Quality Risk Management in pharmaceuticals feels like a high-stakes balancing act. ICH Q9 Quality Risk Management principles sit at the heart of this delicate dance. The main goal of ICH Q9 is to boost drug safety and patient safety through proactive risk assessment. Many companies face implementation challenges that aren’t obvious at first glance.
Pharmaceutical risk management does more than just check compliance boxes. The International Council for Harmonization (ICH) created these guidelines to help develop and maintain safe, effective medicines in the most resource-efficient way. Quality risk management tools and approaches differ among organizations. These inconsistencies can undermine even the best intentions. ICH Q9 offers a powerful framework to manage pharmaceutical risk and protect businesses from threats like adulteration and recalls. Yet many companies miss its full potential because they focus on documentation rather than insight.
In this article, we’ll look at the hidden challenges of putting ICH Q9 guidelines to work and share practical solutions to overcome them. The pharmaceutical industry’s commitment to patient safety and product quality goes beyond regulatory obligations; it’s an ethical must.
Why hidden challenges in QRM go unnoticed
In pharmaceutical companies, beneath their ICH Q9 quality risk management implementation, serious problems often remain hidden. These challenges stay undetected longer than they should.
The illusion of compliance
A simple fact stands out – compliance doesn’t equal quality. Organizations that mix up these concepts create a dangerous illusion that puts patients at risk.
Companies celebrate perfect audit scores while post-market issues pile up. This happens because passing an audit shows only that minimum requirements were met but not excellence in quality. Organizations view quality risk management as a compliance tool. This creates extra work without improving efficiency or reducing cost [1].
This approach turns QRM into what I call “compliance theater” systems built to impress auditors rather than help teams succeed. Teams document what regulators want instead of information that helps make better, faster, safer decisions [2]. Risk assessments end up written to please regulatory inspectors rather than show actual process risks [1].
The formal QRM processes get applied everywhere, which goes against ICH Q9 guidance. The guidance states that “the level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk” [3]. This box-ticking mentality turns meaningful risk analysis into bureaucratic paperwork.
Over-reliance on documentation over insight
Documentation in pharmaceutical quality risk management has become the goal instead of the tool. Papers pile up and hide actual risks instead of showing them clearly.
The traditional “document-centric” approach creates several problems. Teams must track changes manually without defined workflows. Searching across documents becomes a nightmare [4]. This method makes it hard to assess effects when changes happen during development or after launch.
Most recalls, CAPAs, and 483s happen because teams ignore, misunderstand, or misapply procedures not because procedures didn’t exist. This shows a problem with behavior and mindset, not documentation [2]. QRM’s basic purpose gets forgotten: making analytical and scientific decisions early, not justifying choices already made [3].
QRM still adds extra work and cost after 17 years of ICH Q9 implementation [1]. Documentation layers bury the original purpose without addressing real risk.
Example: Passing audits but missing systemic risks
A company’s story shows this clearly. They passed internal audits and got ISO certification. The FDA found CAPA backlogs, incomplete supplier qualifications, and gaps in post-market surveillance data review [5].
Audits stayed narrow, routine, and focused on paperwork rather than results. The company’s audit scope remained static despite new complaints. Teams assessed supplier risks on paper but never checked them on the ground [5].
Medical device companies often fall into this trap. They rely too much on structure like fixed schedules, standard checklists, and narrow compliance views. Programs check boxes but miss evolving risks [5].
Teams auditing familiar peers make things worse. Familiarity leads to soft questions and careful findings. This happens not from hiding truth, but from objectivity fading slowly without notice [5].
Valid issues stay trapped in silos, cut off from trend analysis or management review. Findings don’t move up, and lessons don’t create system-wide improvements [5]. Audits become mere paperwork visible to inspectors but hidden from decision-makers.
Hidden Challenge 1: Inconsistent application of QRM principles
Companies might dodge the compliance trap, but they often fall into another hole: they don’t apply quality risk management principles consistently. I’ve seen pharmaceutical companies where each department reads the ICH Q9 guidelines differently – it’s like they’re working from completely different playbooks!
Variability in how teams interpret ICH Q9
The way different teams handle ICH Q9 quality risk management reminds me of that old story about people trying to describe an elephant while blindfolded. Each person touches a different part and comes up with totally different conclusions. Some teams obsess over documentation, others fixate on risk scoring, and some barely use QRM at all. These differences in interpretations are even more pronounced if a large pharmaceutical enterprise has sites in various locations across the world like the US, Europe, Asia and Australia.
This inconsistency comes in part from ICH Q9’s flexibility – both a blessing and a curse. The guidance specifically states that “the level of effort, formality and documentation of the quality risk management process should be commensurate with the level of risk” [6]. This adaptability helps, but teams often interpret “commensurate” in their own ways.
Risk assessments contain too much subjectivity, which disrupts risk management activities and decision-making [7]. Different stakeholders see hazards, risks, and harms differently. Risk questions don’t have clear definitions, and assessment tools use various scoring methods [7].
Example: Different thresholds for ‘acceptable risk’
Teams set wildly different thresholds for acceptable risk. Here’s what I saw at one manufacturing facility:
QA used a 1-5 scale where scores above 3 needed immediate action
Production worked with a 1-10 scale and set their threshold at 7
R&D used their own risk matrix with color coding
This happens everywhere. Risk thresholds usually work through numeric scales (1-5 or 1-10 for impact and probability), risk matrices, threshold lines, and color coding [8]. Without standard practices, teams end up speaking different risk languages – what’s “high risk” to one is “acceptable” to another. These gaps create dangerous blind spots throughout your quality system.
Risk thresholds play a vital role. They set clear boundaries for acceptable risk and guide decisions about which risks need attention and how quickly [8]. Different thresholds mean teams can’t communicate effectively about risk.
Solution: Centralized QRM governance
A centralized governance approach solves these consistency problems. The best practice shows that “a cross-functional matrix of assigned responsibilities and accountabilities is drawn up and shared with all relevant personnel” [9].
Strong matrix team leadership ended up coordinating QRM between functions and departments of all sizes. This ensures teams define, plan, resource, deploy, and review QRM activities properly [9]. Centralized governance brings three big wins: standardized compliance across the organization, better prevention of problems through earlier detection, and quicker sorting of critical versus non-critical issues [10].
Centralized governance isn’t about more red tape – it’s about clarity. Common risk assessment tools, unified scoring methods, and shared definitions of acceptable risk create a language everyone understands. This helps teams address risks consistently.
Hidden Challenge 2: Poor risk communication across departments
Pharmaceutical companies struggle with more than just technical disagreements when they implement ICH Q9 quality risk management. Their biggest problem? Teams simply can’t communicate effectively about risk.
Lack of shared language and tools
Different departments often fail to communicate because they don’t share a common risk vocabulary. Picture ordering coffee where “medium risk” means something completely different to each team. This creates more than just confusion – it puts safety at risk.
Quality risk management needs experts from quality, product development, regulatory affairs, production operations, and other relevant departments working together [11]. These teams of different backgrounds often find it hard to understand each other.
This communication gap shows up in several ways:
Inconsistent risk terminology across departments
Different interpretations of what constitutes “acceptable risk”
Varied approaches to documenting and sharing risk information
Different priorities about which risks need immediate action
Research reveals that teams without shared risk language leave up to 49% of stakeholders confused about critical situations [3]. Even worse, 35% misunderstand proper medication usage, and 41% can’t properly interpret important labels [3].
Example: QA and production using different risk matrices
Let’s look at a real example. A pharmaceutical company’s Quality Assurance team uses a 5×5 risk matrix while Production works with a simpler 3×3 version [12]. QA marks something as “moderate risk” with a score of 12, but Production sees it as “low risk” scoring only 4.
Nobody takes action until a batch fails testing. Both departments then realize they viewed the same risk through completely different perspectives – similar to measuring temperature with one team using Celsius while another uses Fahrenheit!
Studies show that 37% of professionals admit important information gets lost due to communication barriers [3]. This communication breakdown puts patient safety at risk, especially for those with limited language proficiency who experience more adverse events [3].
Solution: Unified risk taxonomy and SOPs
The fix for this communication mess seems simple: create a shared language for risk.
Standard operating procedures (SOPs) help teams follow consistent protocols for risk communication [13]. These SOPs must clearly spell out what needs to happen, who does it, when it happens, and where regarding risk communication actions [13].
Risk communication must flow both ways – not just from top to bottom [11]. Teams should share details about a risk’s existence, probability, severity, acceptability, and control methods [11].
Creating unified risk communication takes serious organizational commitment. Companies must invest in training that brings teams together to agree on risk definitions, thresholds, and response protocols. This makes both scientific and business sense, since poor communication leads to expensive malpractice claims and patient harm [14].
Hidden Challenge 3: Ignoring lifecycle-based risk review
The third hidden challenge in pharmaceutical quality systems is the “set it and forget it” approach to risk management. Companies invest significant effort in their original risk assessments but then file them away like old yearbook photos that nobody looks at again.
One-time assessments vs. continuous monitoring
That birthday cake you forgot in the refrigerator for months resembles how companies handle their quality risk management documentation. ICH Q9 clearly states that “risk management should be an ongoing part of the quality management process” [6]. Risk management is not a single event but a continuous process.
Companies need to review events that could affect their original risk decisions regularly. These events can be planned (product reviews, inspections, audits) or unplanned (failure investigations, recalls) [6]. Notwithstanding that, many companies still treat risk assessments as a checkbox activity they complete once and never revisit.
Example: No updates after post-market changes
A real-life example stands out from my experience: A pharmaceutical manufacturer completed thorough risk assessments during development. They changed suppliers and modified their packaging process two years after launch. Their risk documentation stayed unchanged. Customer complaints about packaging integrity issues started emerging – issues that proper risk reassessment would have caught early.
This occurs because “the inputs to the risk assessment may change over time — changes in facility conditions, deviation rates, reject rates, or regulatory conditions may affect the living risk assessment” [15]. Of course, ignoring these changes resembles driving with outdated GPS – you’ll end up lost.
Solution: Scheduled risk review cycles
Scheduled risk review cycles provide a practical solution. Higher-risk areas need more frequent reviews, with the frequency “based upon the level of risk” [6]. A lifecycle assessment approach helps maintain a “state of control” baseline and monitors changes over time [15].
Using trend data to trigger reassessment
Your system needs “a consistent set of performance and quality metrics reflecting an end-to-end process” [16]. These metrics serve as an early warning system and trigger reassessments when trends shift. “Blind control samples” tested periodically verify your system’s stability [2]. This approach makes continuous monitoring both economical and preventative.
Hidden Challenge 4: Failure to link QRM to business outcomes
Money talks in pharmaceutical quality, yet companies often miss crucial financial signals during ICH Q9 quality risk management implementation. Balance sheets rarely show QRM’s financial effects, which creates a dangerous gap between quality initiatives and business outcomes.
Risk management seen as a compliance checkbox
Most pharma companies treat quality risk management as a regulatory requirement rather than a business advantage. This mindset turns QRM into a cost burden instead of a value creator. Companies manage Quality Management and Risk Management separately, which leads to operational blind spots and makes them vulnerable to compliance issues and process inefficiencies [17].
Why does this happen? QRM loses its strategic value once it disconnects from business goals. Companies budget for it like insurance they hope not to use, without expecting any measurable returns.
Example: No ROI tracking for risk mitigation efforts
Consider this scenario: Your company spends $500,000 to implement new controls after a risk assessment. The CFO asks about the return on investment, but the quality team can only mention “regulatory compliance” without showing tangible benefits.
Traditional ROI focuses on clear revenue metrics, while risk management ROI looks at cost savings and loss prevention—which proves hard to measure [18]. The challenge lies in measuring prevented incidents. Successful risk management means potential costs like legal fees or business disruptions never materialize [18].
Solution: Aligning QRM metrics with business KPIs
QRM remains vital to any biopharmaceutical quality system. Our team at Biostrategenix brings real-life experience in designing and deploying balanced QRM systems. This challenge needs a collaborative approach.
The answer lies in connecting QRM efforts to specific business outcomes. KPIs act as bridges between company goals and actual results [19]. Quality metrics that line up with business objectives ensure risk management supports strategic targets [19].
To cite an instance, companies taking a proactive approach to risk management limit unexpected quality failures by 40% compared to reactive processes [17]. This affects the bottom line because a risk-based quality management system reduces compliance incidents by 33% and cuts regulatory penalties [17].
Cost-benefit analysis of risk controls
Business thinking should guide risk control decisions. Each risk mitigation measure needs cost-benefit analysis to weigh setup costs against expected returns. Research shows proper implementation of pharmaceutical information systems yielded benefits 2.6 times higher than costs [20].
Note that risk management goes beyond problem prevention—it enables smarter business choices that protect patients and profits alike.
Conclusion
Managing ICH Q9 quality risk management is like cooking a gourmet meal. The ingredients (guidelines) might be perfect. Without the right technique (implementation), you’ll likely end up with a disappointing dish. Companies focus heavily on documentation and compliance. They miss the deeper purpose of QRM – making better decisions that protect patients and support business goals.
These challenges aren’t theoretical. They create real barriers that stop pharmaceutical companies from realizing their quality systems’ full potential. Blind spots emerge from inconsistent application. Missed signals result from poor communication. One-time assessments become outdated quickly. Risk management becomes an expense rather than an investment when it disconnects from business outcomes.
The way forward needs an integrated approach. Everyone understands a common language through standardized risk assessment methods. Risks don’t fall through departmental cracks with cross-functional teams and clear communication channels. Risk assessments stay relevant as products and processes evolve through regular review cycles. QRM plays a vital role in any biopharmaceutical quality system. Biostrategenix has direct experience in creating and implementing a balanced QRM system. We should tackle this challenge together.
Quality risk management that works isn’t about perfect documentation – it’s about perfect execution. Smart companies don’t just follow ICH Q9. They welcome its principles as a framework to make better decisions. Quality builds the foundation for lasting success rather than opposing efficiency.
Think of QRM as your pharmaceutical quality GPS. When fine-tuned and updated often, it does more than help avoid hazards. It shows shortcuts and opportunities you might miss otherwise. Excellence in manufacturing begins by facing these hidden challenges directly. Your patients, regulators, and shareholders will thank you.
Key Takeaways
These insights reveal the critical gaps between ICH Q9 compliance and effective quality risk management implementation that pharmaceutical companies must address to protect patients and business outcomes.
• Move beyond compliance theater: True QRM success requires focusing on actionable insights rather than documentation that merely satisfies auditors and regulatory requirements.
• Standardize risk communication across departments: Implement unified risk matrices, terminology, and SOPs to prevent dangerous miscommunication between QA, production, and other teams.
• Establish continuous risk monitoring cycles: Replace one-time assessments with scheduled reviews triggered by trend data, process changes, and post-market surveillance findings.
• Link QRM directly to business KPIs: Track ROI of risk mitigation efforts and align quality metrics with business outcomes to demonstrate tangible value beyond regulatory compliance.
• Create centralized QRM governance: Deploy cross-functional teams with standardized tools and clear accountability matrices to ensure consistent risk assessment across all departments.
When properly implemented, ICH Q9 transforms from a regulatory burden into a strategic advantage that drives both patient safety and business performance through data-driven decision making.
References
[1] – https://arriello.com/article/quality-risk-management-ich-q9-as-an-enabler-of-integrated-quality-management/
[2] – https://www.americanpharmaceuticalreview.com/Featured-Articles/517625-Risk-Based-Test-Method-Development-Validation-and-Life-Cycle/
[3] – https://pmc.ncbi.nlm.nih.gov/articles/PMC7201401/
[4] – https://sunstonepilot.com/2017/01/dont-rely-on-documents-to-manage-your-documentation/
[5] – https://www.nsf.org/knowledge-library/internal-audits-arent-catching-what-matters-a-risk-you-cant-ignore
[6] – https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonization-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q9-quality-risk-management-step-5-first-version_en.pdf
[7] – https://www.fda.gov/media/177720/download
[8] – https://trustedinstitute.com/concept/pmi-rmp/risk-thresholds-triggers/risk-thresholds-in-risk-prioritization/
[9] – https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/production/trs981-annex2-who-quality-risk-management.pdf
[10] – https://www.thefdagroup.com/blog/using-quality-risk-management-to-cultivate-a-culture-of-quality
[11] – https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonization-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-q9-r1-quality-risk-management-step-5-revision-2_en.pdf
[12] – https://www.vectorsolutions.com/resources/blogs/risk-matrix-calculations-severity-probability-risk-assessment/
[13] – https://thecompassforsbc.org/project-examples/national-standard-operating-procedures-risk-communication-and-social-mobilization
[14] – https://www.qualityhealth.org/wpsc/2017/10/13/impact-of-language-cultural-barriers-on-patient-safety-health-equity/
[15] – https://www.outsourcedpharma.com/doc/how-to-enable-your-quality-risk-management-lifecycle-0001
[16] – https://www.appliedclinicaltrialsonline.com/view/data-management-efficiencies-through-risk-based-approaches-and-innovations
[17] – https://www.qualityze.com/blogs/quality-risk-management
[18] – https://www.resolver.com/blog/roi-in-risk-management/
[19] – https://www.complyassistant.com/resources/risk-management/top-metrics-how-to-use-kpis-to-track-third-party-risk-management-effectiveness/
[20] – https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.925287/full
Leave a Reply